{"ticker": {"uuid": "6ed5d056-44e6-45da-a7f9-2eca74715a24", "symbol": "CMPX", "name": "Compass Therapeutics Inc.", "exchange": "NASDAQ", "country": "US", "sector": "Healthcare", "industry": "Biotechnology"}, "articles": [{"title": "Q1 Earnings Highs And Lows: Natera (NASDAQ:NTRA) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMilAFBVV95cUxNYmZ3aHMyMjBuNmlEUGN6NWZBZV85cEFWNndJaVNoNEVYNk84MlNKRXJ0RXpRQl9wN1RsekhxM3loY1RRNDJhTnVremtReHhLQWVHS053VzRBUTduSkdqRGt1YkxMMThqZHoydElPX1Zfd3hEMi15VlRwRGRvZ2JqRDFneVVxN0JCYzQ4QlV5TTBEOWx3?oc=5", "source_name": "Market source", "published_at": "2026-07-16T18:49:22+00:00", "published_display": "16 Jul 2026 18:49", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Compass Therapeutics: A 50% Price Cut Hiding A Regulatory Mispricing Opportunity", "summary": "", "url": "https://news.google.com/rss/articles/CBMixgFBVV95cUxOUjRVUmJWU2hZbFBHelhoWmJ6b3FpMnlWY0FBT3VZWkNaTEEwYXUwVWEyUzliZ2JZaTItb21kbzRDX3BnS3haNUhCSmV3QWhVN1R0NnZ6NThwMFplb1pQbWJMR2NnaGxoRmpaV1RYX1J4MnB3RUNFcVBYb3NLWVdrMk51b0VvM0NJc2FOZkQ4dlFZMGxXODlnRE1WM0V6b3RlSVN1Z0kxRWdSbHRBdUwwdVBIQklEa2I5eDZ4OTJENFkwQXI5RlE?oc=5", "source_name": "Seeking Alpha", "published_at": "2026-07-15T18:31:30+00:00", "published_display": "15 Jul 2026 18:31", "sentiment": "negative", "sentiment_pct": 34, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Compass Therapeutics Inc. (CMPX) Institutional Confidence", "summary": "", "url": "https://news.google.com/rss/articles/CBMicEFVX3lxTE5YSy1GQmg3QS0tbGFwMmpQNVVKTmozU0taOTJmeGxzS01mbHl4NGlXUWhyVDdKOEw4TXdQbHZHLUgtQ3daS0FTd0dGM3h2cFBTNmY4QlVUQzdWYnRqUm9xQlUxeUxGV29HWloyTmxXQkI?oc=5", "source_name": "TradingKey", "published_at": "2026-07-13T07:00:00+00:00", "published_display": "13 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMigAJBVV95cUxPV1hqSFhQM3VfYlNsdldfeVQ1dEdNNzI3S1RTaFJNSThrOXlPSWpMTlR5WWVxNnNsTzhTVGVvTE94R18wa1A0OUdFczBlcTIzeUFBZUt6VVJJMjNqNks3dmRUSzB4cE40anpNekJwUXAwcTFEcVh4QVZCYURXY2w4b2thdk5KZ3ZJMnI1REJObXo5UDdISXVCU1Z2ZVZoVmJpbnEzaDVWVmpGQVNFZzRXYnp0SWRRWWZGSnZnWlJ4aEloNmJBNGRMVFRjb3ZRbmV3QXF5S0pvTV9xNnpaMWV1Z1ZtM3lPdV9RcEdURHlfZFphdjlicEJndW0ybHNBa205?oc=5", "source_name": "The Globe and Mail", "published_at": "2026-07-13T03:32:00+00:00", "published_display": "13 Jul 2026 03:32", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Compass Therapeutics (CMPX) Goldman Sachs 47th Annual Global Healthcare Conference 2026 summary", "summary": "Compass Therapeutics presented at the Goldman Sachs 47th Annual Global Healthcare Conference, highlighting progress on four clinical-stage oncology drugs. The lead asset, tovecimig, is advancing toward potential FDA BLA filing and showed significant efficacy in a phase II/III BTC", "url": "https://quartr.com/events/compass-therapeutics-inc-cmpx-goldman-sachs-47th-annual-global-healthcare-conference-2026_Fe3v2EAo", "source_name": "Quartr", "published_at": "2026-07-08T13:40:55", "published_display": "08 Jul 2026 13:40", "sentiment": "positive", "sentiment_pct": 75, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "CMPX Stock Has Retail Buzzing Ahead Of High-Stakes Cancer Drug Trial Update", "summary": "Compass Therapeutics (CMPX), a biotech company, is generating significant retail investor interest ahead of its Phase 2/3 trial data release for its cancer drug Tovecimig, used to treat advanced biliary tract cancer. The drug, in combination with Paclitaxel, has shown promising e", "url": "https://stocktwits.com/news-articles/markets/equity/cmpx-stock-retail-buzzing-ahead-of-cancer-drug-trial-update/cZBNZa7Re2t", "source_name": "Stocktwits", "published_at": "2026-07-07T20:11:35", "published_display": "07 Jul 2026 20:11", "sentiment": "negative", "sentiment_pct": 42, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "If You Invested $1,000 in Compass Therapeutics Inc (CMPX)", "summary": "This article analyzes the historical performance of investing $1,000 in Compass Therapeutics Inc (CMPX) over different periods, detailing the current worth of such an investment and its annual returns. It also provides a comprehensive overview of Compass Therapeutics, a clinical-", "url": "https://www.stocktitan.net/tools/stock-return-calculator/CMPX", "source_name": "Stock Titan", "published_at": "2026-07-05T00:40:29", "published_display": "05 Jul 2026 00:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Here\u2019s Why Citizens Maintains a Buy on Compass Therapeutics (CMPX)", "summary": "Citizens has reiterated a Market Outperform rating on Compass Therapeutics (CMPX) with a $10 price target after the company presented promising clinical data at the ASCO conference for its bispecific antibody, CTX-8371. This drug showed early signs of activity in treating difficu", "url": "https://www.insidermonkey.com/blog/heres-why-citizens-maintains-a-buy-on-compass-therapeutics-cmpx-1794179/", "source_name": "Insider Monkey", "published_at": "2026-07-03T13:39:52", "published_display": "03 Jul 2026 13:39", "sentiment": "positive", "sentiment_pct": 72, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 93, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Bronstein, Gewirtz & Grossman, LLC Is Investigating Compass Thera", "summary": "Bronstein, Gewirtz & Grossman, LLC is investigating potential claims against Compass Therapeutics, Inc. (CMPX) following a significant drop in its stock price. The investigation stems from an April 27, 2026 announcement regarding a phase 2/3 study for its drug tovecimig, which, d", "url": "https://natlawreview.com/press-releases/bronstein-gewirtz-grossman-llc-investigating-compass-therapeutics-inc-cmpx", "source_name": "The National Law Review", "published_at": "2026-07-02T06:09:32", "published_display": "02 Jul 2026 06:09", "sentiment": "negative", "sentiment_pct": 18, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Compass updates corporate presentation, reports positive Phase 2/3 COMPANION-002 BTC data and plans BLA engagement", "summary": "Compass Therapeutics (`CMPX`) has updated its corporate presentation, revealing positive Phase 2/3 COMPANION-002 data for tovecimig in second-line biliary tract cancer (BTC). The data shows improved objective response rate (ORR) and progression-free survival (PFS) for a combinati", "url": "https://www.tradingview.com/news/tradingview:f4058c1d815a9:0-compass-updates-corporate-presentation-reports-positive-phase-2-3-companion-002-btc-data-and-plans-bla-engagement/", "source_name": "TradingView", "published_at": "2026-07-01T20:39:45", "published_display": "01 Jul 2026 20:39", "sentiment": "positive", "sentiment_pct": 82, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Compass Therapeutics (NASDAQ: CMPX) targets BLA after biliary tract cancer trial success", "summary": "Compass Therapeutics' tovecimig, in combination with paclitaxel, showed significant improvement in overall response rate (18.0% vs. 5.3%) and progression-free survival (4.7 months vs. 2.6 months) in a Phase 2/3 trial for second-line biliary tract cancer. The company plans an FDA ", "url": "https://www.stocktitan.net/sec-filings/CMPX/8-k-compass-therapeutics-inc-reports-material-event-cda7ae44b8fc.html", "source_name": "Stock Titan", "published_at": "2026-07-01T20:39:45", "published_display": "01 Jul 2026 20:39", "sentiment": "positive", "sentiment_pct": 71, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Bronstein, Gewirtz & Grossman, LLC Encourages Compass Therapeutic", "summary": "Bronstein, Gewirtz & Grossman, LLC is investigating potential claims against Compass Therapeutics, Inc. (CMPX) following a significant drop in its stock price. This decline occurred after the company announced phase 2/3 study results for its drug tovecimig, which met a key second", "url": "https://natlawreview.com/press-releases/bronstein-gewirtz-grossman-llc-encourages-compass-therapeutics-inc-cmpx-0", "source_name": "The National Law Review", "published_at": "2026-07-01T19:41:12", "published_display": "01 Jul 2026 19:41", "sentiment": "negative", "sentiment_pct": 8, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to earnings forward of Compass Therapeutics, Inc. \u2013 NASDAQ:CMPX", "summary": "This article focuses on the \"Price to earnings forward\" financial metric for Compass Therapeutics, Inc. (NASDAQ: CMPX). While the article title presents this topic, there is no actual data or discussion provided within the content. The body of the article appears to be primarily ", "url": "https://www.tradingview.com/symbols/NASDAQ-CMPX/financials-statistics-and-ratios/price-earnings-fwd/", "source_name": "TradingView", "published_at": "2026-07-01T01:12:44", "published_display": "01 Jul 2026 01:12", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to sales forward of Compass Therapeutics, Inc. \u2013 NASDAQ:CMPX", "summary": "This page displays the \"Price to sales forward\" metric for Compass Therapeutics, Inc. (NASDAQ: CMPX) as provided by TradingView. The content primarily focuses on financial data for the company within the Pharmaceuticals: Major sector and indicates market closure with no current t", "url": "https://www.tradingview.com/symbols/NASDAQ-CMPX/financials-statistics-and-ratios/price-sales-fwd/", "source_name": "TradingView", "published_at": "2026-06-29T22:10:06", "published_display": "29 Jun 2026 22:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to revenue forward of Compass Therapeutics, Inc. \u2013 NASDAQ:CMPX", "summary": "This article focuses on the \"Enterprise value to revenue forward\" metric for Compass Therapeutics, Inc. (NASDAQ: CMPX). The content is primarily a header with navigation and footer details, indicating a financial data point for the company on the TradingView platform.", "url": "https://www.tradingview.com/symbols/NASDAQ-CMPX/financials-statistics-and-ratios/enterprise-value-sales-fwd/", "source_name": "TradingView", "published_at": "2026-06-29T16:41:25", "published_display": "29 Jun 2026 16:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Compass Therapeutics, Inc.(NasdaqCM:CMPX) dropped from Russell 3000E Growth Benchmark", "summary": "Compass Therapeutics, Inc. (NasdaqCM:CMPX), a clinical-stage biopharmaceutical company focused on oncology therapeutics, has been dropped from the Russell 3000E Growth Benchmark. The company's stock shows a 5-day change of +0.48% and a year-to-date change of -61.27%. Compass Ther", "url": "https://www.marketscreener.com/news/compass-therapeutics-inc-nasdaqcm-cmpx-dropped-from-russell-3000e-growth-benchmark-ce7f5fdeda81f424", "source_name": "www.marketscreener.com", "published_at": "2026-06-29T05:40:07", "published_display": "29 Jun 2026 05:40", "sentiment": "negative", "sentiment_pct": 28, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Compass Therapeutics, Inc.(NasdaqCM:CMPX) dropped from Russell Small Cap Comp Growth Benchmark", "summary": "Compass Therapeutics, Inc. (NasdaqCM:CMPX) has been removed from several Russell benchmarks, including the Russell Small Cap Comp Growth Benchmark, Russell 3000 Growth Benchmark, and Russell Microcap Growth Benchmark Index. This news follows a recent downgrade by Raymond James an", "url": "https://www.marketscreener.com/news/compass-therapeutics-inc-nasdaqcm-cmpx-dropped-from-russell-small-cap-comp-growth-benchmark-ce7f5fdcdb88f721", "source_name": "marketscreener.com", "published_at": "2026-06-28T22:10:06", "published_display": "28 Jun 2026 22:10", "sentiment": "negative", "sentiment_pct": 39, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Compass Therapeutics, Inc. Actuals & Estimates (NASDAQ:CMPX)", "summary": "This article provides an overview of Compass Therapeutics, Inc. (NASDAQ:CMPX) stock data, including its current price, historical performance, and analyst forecasts. It also details the company's financial actuals and estimates, discusses upcoming earnings reports, and provides a", "url": "https://www.tradingview.com/symbols/NASDAQ-CMPX/forecast-actuals-and-estimates/", "source_name": "TradingView", "published_at": "2026-06-25T20:10:07", "published_display": "25 Jun 2026 20:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "CMPX Forecast \u2014 Price Target \u2014 Prediction for 2027", "summary": "This article provides a forecast and price target for Compass Therapeutics, Inc. (CMPX) stock for 2027 based on analyst opinions. It includes current stock performance, historical highs and lows, volatility metrics, and key financial information like recent earnings, revenue, and", "url": "https://www.tradingview.com/symbols/NASDAQ-CMPX/forecast-price-target/", "source_name": "TradingView", "published_at": "2026-06-25T18:42:34", "published_display": "25 Jun 2026 18:42", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Compass Therapeutics Inc. (CMPX) Valuation: PE, PB & Fair Value Analysis", "summary": "This article provides a valuation analysis for Compass Therapeutics Inc. (CMPX), highlighting its current valuation score, market capitalization, and P/E ratio. As of June 26, 2026, the company's valuation score is 8.69, ranking 104 out of 387 in the Biotechnology & Medical Resea", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-cmpx/company-valuation", "source_name": "TradingKey", "published_at": "2026-06-24T08:10:58", "published_display": "24 Jun 2026 08:10", "sentiment": "negative", "sentiment_pct": 38, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Compass Therapeutics (CMPX) Stock Forecast & Analyst Ratings", "summary": "This article provides a stock forecast and analyst ratings for Compass Therapeutics (CMPX). It serves as a resource for investors looking for insights into the company's financial prospects and market sentiment.", "url": "https://www.moomoo.com/stock/CMPX-US/forecast?chain_id=Name1K9-3FXPhg.1ku86o0&global_content=%7B%22promote_id%22%3A%2213764%22,%22sub_promote_id%22%3A%2280%22,%22f%22%3A%22www.moomoo.com%2Fsg%2Flearn%2Fdetail-why-dividend-stocks-can-be-beneficial-to-investors-90963-230159001%22%7D", "source_name": "Moomoo", "published_at": "2026-06-23T13:09:58", "published_display": "23 Jun 2026 13:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Compass Therapeutics Inc. (CMPX) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution", "summary": "This article provides a revenue breakdown for Compass Therapeutics Inc. (CMPX), noting that essential financial data such as business segments, regional revenue, and profit contribution have not yet been disclosed by the company. It only shows a placeholder for \"United States\" wi", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-cmpx/revenue", "source_name": "TradingKey", "published_at": "2026-06-17T17:39:33", "published_display": "17 Jun 2026 17:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "How Compass Therapeutics (CMPX) Is Moving Tovecimig Toward a Potential Biliary Tract Cancer Filing", "summary": "Compass Therapeutics (CMPX) is advancing its experimental cancer treatment, tovecimig, for biliary tract cancer, having received FDA Orphan Drug Designation and planning an approval application later in 2026. The company reported strong tumor response in late-stage studies and ha", "url": "https://www.insidermonkey.com/blog/how-compass-therapeutics-cmpx-is-moving-tovecimig-toward-a-potential-biliary-tract-cancer-filing-1783031/", "source_name": "Insider Monkey", "published_at": "2026-06-17T11:16:00", "published_display": "17 Jun 2026 11:16", "sentiment": "positive", "sentiment_pct": 71, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Compass Therapeutics Inc. (CMPX) Earnings Forecast: Future EPS & Revenue Growth Estimates", "summary": "This article provides an earnings forecast for Compass Therapeutics Inc. (CMPX), highlighting its current earnings forecast score of 8.67 and ranking within the Biotechnology & Medical Research industry. It details analyst ratings, revealing a strong \"Buy\" consensus with an avera", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-cmpx/earnings", "source_name": "TradingKey", "published_at": "2026-06-17T08:11:00", "published_display": "17 Jun 2026 08:11", "sentiment": "positive", "sentiment_pct": 71, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Compass Therapeutics Inc. (CMPX) Financial Health: Profitability & Balance Sheet Analysis", "summary": "This article provides an analysis of Compass Therapeutics Inc. (CMPX) financial health, highlighting its current financial score of 6.36, which ranks it 257 out of 388 in the Biotechnology & Medical Research industry. While the company's financial status is considered robust, its", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-cmpx/financial-health", "source_name": "TradingKey", "published_at": "2026-06-17T08:11:00", "published_display": "17 Jun 2026 08:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Compass Therapeutics Inc. (CMPX) Technical Analysis: Support, Resistance, Indicators & Moving Averages", "summary": "This article provides a technical analysis of Compass Therapeutics Inc. (CMPX), detailing its current price momentum score, support and resistance levels, and indicator readings (MACD, RSI, KDJ, etc.) and moving averages. According to the analysis, CMPX currently has a price mome", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-cmpx/technical", "source_name": "TradingKey", "published_at": "2026-06-17T08:11:00", "published_display": "17 Jun 2026 08:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "5 Small Cap Stocks with Potential to Rise 1000 Percent", "summary": "This article highlights Compass Therapeutics, Inc. (NASDAQ: CMPX) as a small-cap stock with significant growth potential, possibly rising 1000 percent. The company is developing tovecimig, an experimental cancer treatment that recently received FDA Orphan Drug Designation and sho", "url": "https://www.insidermonkey.com/blog/5-small-cap-stocks-with-potential-to-rise-1000-percent-1782074/3/", "source_name": "Insider Monkey", "published_at": "2026-06-16T13:10:07", "published_display": "16 Jun 2026 13:10", "sentiment": "positive", "sentiment_pct": 70, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Compass Therapeutics Shareholders Back Directors, Pay, Auditor Oversight", "summary": "Compass Therapeutics, Inc. shareholders recently re-elected two Class III directors, Thomas J. Schuetz and Richard S. Lindahl, and ratified CohnReznick, LLP as their independent auditor. Investors also approved the compensation for executive officers and supported an annual advis", "url": "https://www.theglobeandmail.com/investing/markets/stocks/CMPX-Q/pressreleases/2448480/compass-therapeutics-shareholders-back-directors-pay-auditor-oversight/", "source_name": "The Globe and Mail", "published_at": "2026-06-14T05:40:56", "published_display": "14 Jun 2026 05:40", "sentiment": "negative", "sentiment_pct": 39, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Transcript : Compass Therapeutics, Inc. Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026, Jun-09-2026 08", "summary": "This article is a transcript of Compass Therapeutics, Inc.'s presentation at the Goldman Sachs 47th Annual Global Healthcare Conference held on June 9, 2026. The presentation started at 8:00 AM. The full article content is reserved for subscribers.", "url": "https://www.marketscreener.com/news/transcript-compass-therapeutics-inc-presents-at-goldman-sachs-47th-annual-global-healthcare-conf-ce7f5cdad981f724", "source_name": "www.marketscreener.com", "published_at": "2026-06-13T17:40:13", "published_display": "13 Jun 2026 17:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Compass Therapeutics (NASDAQ: CMPX) investors back board, auditor and pay in 2026 votes", "summary": "Compass Therapeutics, Inc. stockholders approved all proposals at their annual meeting on June 10, 2026. This included re-electing Class III directors Thomas J. Schuetz and Richard S. Lindahl, ratifying CohnReznick LLP as the independent auditor, and approving executive compensat", "url": "https://www.stocktitan.net/sec-filings/CMPX/8-k-compass-therapeutics-inc-reports-material-event-57f69defd0e2.html", "source_name": "Stock Titan", "published_at": "2026-06-12T15:09:16", "published_display": "12 Jun 2026 15:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "CMPX: Lead oncology asset tovecimig nears FDA filing after strong BTC trial results; multiple catalysts ahead", "summary": "Compass Therapeutics (CMPX) is advancing four oncology assets, with its lead drug, tovecimig, showing strong efficacy in BTC and nearing FDA submission. The company anticipates multiple clinical and regulatory catalysts within the next year and has a cash runway extending into 20", "url": "https://www.tradingview.com/news/urn:summary_document_transcript:quartr.com:3531568:0-cmpx-lead-oncology-asset-tovecimig-nears-fda-filing-after-strong-btc-trial-results-multiple-catalysts-ahead/", "source_name": "TradingView", "published_at": "2026-06-09T13:09:50", "published_display": "09 Jun 2026 13:09", "sentiment": "positive", "sentiment_pct": 71, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Compass Therapeutics Eyes FDA Path After Tovecimig Trial Win", "summary": "Compass Therapeutics is preparing for an FDA meeting in early August regarding its drug tovecimig, a DLL4/VEGF bispecific antibody, after successful trial results in advanced biliary tract cancer. The COMPANION-002 study met its primary endpoint of overall response rate and signi", "url": "https://www.barchart.com/story/news/2378475/compass-therapeutics-eyes-fda-path-after-tovecimig-trial-win", "source_name": "Barchart", "published_at": "2026-06-09T03:10:06", "published_display": "09 Jun 2026 03:10", "sentiment": "positive", "sentiment_pct": 73, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Analysts Offer Insights on Healthcare Companies: Praxis Precision Medicines (PRAX), Compass Therapeutics (CMPX) and Tenax Therapeutics (TENX)", "summary": "This article highlights bullish sentiments from three analysts regarding several healthcare companies. Douglas Tsao from H.C. Wainwright reiterated a Buy rating on Praxis Precision Medicines (PRAX) with a $1245.00 price target. Biren Amin from Piper Sandler maintained a Buy ratin", "url": "https://www.theglobeandmail.com/investing/markets/stocks/PRAX/pressreleases/2259986/analysts-offer-insights-on-healthcare-companies-praxis-precision-medicines-prax-compass-therapeutics-cmpx-and-tenax-therapeutics-tenx/", "source_name": "The Globe and Mail", "published_at": "2026-06-02T13:39:09", "published_display": "02 Jun 2026 13:39", "sentiment": "positive", "sentiment_pct": 77, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Stifel Maintains Compass Therapeutics(CMPX.US) With Buy Rating, Maintains Target Price $6", "summary": "Stifel has reiterated its Buy rating for Compass Therapeutics (CMPX.US) and maintained its price target of $6. The article indicates a continued positive outlook from the financial firm regarding the company's stock.", "url": "https://www.moomoo.com/news/post/70866944/stifel-maintains-compass-therapeutics-cmpxus-with-buy-rating-maintains-target", "source_name": "Moomoo", "published_at": "2026-06-02T10:39:09", "published_display": "02 Jun 2026 10:39", "sentiment": "positive", "sentiment_pct": 75, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Compass Therapeutics to Participate in Upcoming June Investor Events", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/compass-therapeutics-participate-upcoming-june-113000218.html", "source_name": "GlobeNewswire", "published_at": "2026-05-28T11:30:00+00:00", "published_display": "28 May 2026 11:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Compass Therapeutics to Present Promising Phase 1 Clinical Data for CTX-8371 in Patients with Advanced Malignancies Treated in the Post-Checkpoint Inhibitor Setting at the 2026 ASCO Annual Meeting", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "GlobeNewswire", "published_at": "2026-05-21T07:00:00+00:00", "published_display": "21 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Compass Therapeutics, Inc. - CMPX", "summary": "", "url": "https://news.google.com/rss/articles/CBMi-wFBVV95cUxPR2RNMjBRWUhhSGFpZVF1T2pReE05azVLOHhKSzdzd1NuMDFiY0RCb204T1JoUFVpVXhBdXlQR3FGRzdyRkZWVllOb2RjTVhYbzhVa2tiVTFRTU9vMU0xSkk3TU1JeEN4eVBtcE9MeWpka1lTMGowOVFoR01aM0cxZ0QzcmZmVmxVcm1TclE4ZzQxVzA0bjE0RG9HWFFoblc1TVRtMF81THlLZzBiM3FZVHFYY01WS1hvc0pEUW5xa0dJcS1mWHFzWVl4UkJ2UjFFWU9rY1lxcTJXOG5FeHRDMUdRVFF5NDUwLUFMUmNmNmZ3a3ZacjREazhpVQ?oc=5", "source_name": "PR Newswire", "published_at": "2026-05-21T07:00:00+00:00", "published_display": "21 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Compass Therapeutics (CMPX) Reports Q1 2026 Net Loss of $18.3M", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/compass-therapeutics-cmpx-reports-q1-045005286.html", "source_name": "Insider Monkey", "published_at": "2026-05-18T04:50:05+00:00", "published_display": "18 May 2026 04:50", "sentiment": "negative", "sentiment_pct": 42, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Compass Therapeutics to Participate in Upcoming May Investor Events", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/compass-therapeutics-participate-upcoming-may-113000196.html", "source_name": "GlobeNewswire", "published_at": "2026-05-12T11:30:00+00:00", "published_display": "12 May 2026 11:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Canaccord Maintains Buy Rating on Compass Therapeutics (CMPX)", "summary": "", "url": "https://finance.yahoo.com/markets/stocks/articles/canaccord-maintains-buy-rating-compass-121653644.html", "source_name": "Insider Monkey", "published_at": "2026-05-05T12:16:53+00:00", "published_display": "05 May 2026 12:16", "sentiment": "positive", "sentiment_pct": 58, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Compass Therapeutics Reports 2026 First Quarter Financial Results and Provides Corporate Update", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/compass-therapeutics-reports-2026-first-113000530.html", "source_name": "GlobeNewswire", "published_at": "2026-05-05T11:30:00+00:00", "published_display": "05 May 2026 11:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Does Compass Therapeutics' (CMPX) Biliary Cancer Data Hint At A Broader Pipeline Re\u2011Rating Opportunity?", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqwFBVV95cUxQZnFCYUpZOVc1WWNVRlhrTHhmTXhDT3AtR0ZHU1lPQl9yZ3A2VE1odVlJbXJNM3laZV9BUFdieUJna3NMRnhsR1RKb3JYNUUta3VxNmQ5TTIxZ3F2U2hRdlJBNnFBMmVaVlFtZnhGemljbGZOYnZIMDlDU3pEc091c2dZcEJ5Y1JscFB6MmZTcC1RU0Jma2xxZnBBZ181RjB6dWo5TkZGMlNDdDA?oc=5", "source_name": "Market source", "published_at": "2026-04-29T07:00:00+00:00", "published_display": "29 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Compass Therapeutics\u2019s stock crashes after OS miss in BTC trial", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqgFBVV95cUxQZmFCT1dhdHpGTmJFSmNaZUl3M3dlcFB2d0tjbDJUdDhROU83Z1EyQXNwZlBHTGpXbWtWcDlyVmctX3pTdDVZVl8wSlRlSEhvWEF2TTE4djd2T3dzTFpZVU90M1lGdDZrREszcUhzcUNQSjVNam5GZjFJN2N3U1NCWnNxZndLOWt5Tm1BblZjcFBOaVplenhxdC1FSWtTUm10aDlKcmZ3Ql9YUQ?oc=5", "source_name": "Market source", "published_at": "2026-04-28T07:00:00+00:00", "published_display": "28 Apr 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Compass Therapeutics stock tumbles after trial data", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPc0VJcVZqdjYxcjZmRzFQVVBfOFlpTV9qVDZqd1NycGtSYUdHQnZ6SEQ1Q3NUT25ybENKdkxhZmE4RGpCekNpVnFIZ0RESzJXRE9mNnl0eE1EVmVHTVJnSTYxaUtTcnB6U1hpakQyOUhYaUFvZEJzMWFUbk1DR2V5d3lnOWxLcVhDUmhxeEEyMzd1cEp2bTFSY0tlbDlvWDRINjN3eEVrVzlBaS1NTl9FLWUwNA?oc=5", "source_name": "Investing.com", "published_at": "2026-04-27T07:00:00+00:00", "published_display": "27 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "CMPX Stock Slides As Volatility Grips Compass Therapeutics", "summary": "", "url": "https://news.google.com/rss/articles/CBMiggFBVV95cUxNdU1SNjk0WTVuUVoxbnhpUDNsczRJdjVYSV9GMXVkQTBzSVlYd1VDaVdBU2ttR1luaHk1NVZzdER5d3ZrVW9FUUJhbXY0dGFneWJwWUFveEVLamNZLXB5RWhHMFMteE5PZnF6M0ZtaHRiQUllV05IZ0tMOFBRNlU4Skt3?oc=5", "source_name": "timothysykes.com", "published_at": "2026-04-27T07:00:00+00:00", "published_display": "27 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Compass Therapeutics, Inc.'s (NASDAQ:CMPX) Path To Profitability", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqAFBVV95cUxOc0RJN3p1YU1tS3Q4LWc3UXZKQnUwOHcxM3QzQVZTcGNBQlVaSWNZOHd2QU04NzF1Qm1NV1UtMzZpd25LZFZMQUpxVjFBQjhpVTl3X1pqM0lnSGlMV1B0RkJuYXA2UnF1cDA0NWdRbG1TbkFIamo5UWJDcUZ4TGJKSmJYU0NnQVVhbnp0SmJIQjM4SnVSUVpycTdKT1hMTHl1T1N3alRqc0k?oc=5", "source_name": "Market source", "published_at": "2026-04-26T07:00:00+00:00", "published_display": "26 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Compass Therapeutics, Inc. (CMPX) Up 200% Year-on-Year", "summary": "", "url": "https://news.google.com/rss/articles/CBMipAFBVV95cUxOdUJJaF9tRXFGQ3M1djhzaXNvbUdMYnh4Q2VUZjA5VTZ5ZGl0LVNLeVc0RUVobXFWdzRpeTZENFpmaUtqTzMxUmU2VVh5QlQxb2lPZ3VIQ3FCX25oLVNUdkhOV0VKcERaWDVQdTVib21UT1ZhTXBKWTMxU01DdnhwUXlkZ1NpUnlfOUZsRXdzbnEwOXk3SUFUSFZCR2stOGFmMzRadw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "What Compass Therapeutics (CMPX)'s Pipeline Progress And 2025 Losses Reveal About Its Oncology Strategy", "summary": "", "url": "https://news.google.com/rss/articles/CBMikwFBVV95cUxNNERXM3JRYjhsM0FhSHFCQ0l0clAwS2R2Wkp3TW1oRGdYdVdNWURoalF0akNGVDRBc2N6VktUYjFWekVJRjZWcTl6WWRDc2RvZF9pSG5QcTFnajV0QXEyZmhhZlJJMzJxeFV4WDlRTFhmTmdkRGh4VEM3cUxDT0J1VnJkUkU1YjhXeW1IWUFkMGdJLUk?oc=5", "source_name": "Market source", "published_at": "2026-03-09T07:00:00+00:00", "published_display": "09 Mar 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Compass Therapeutics, Inc. (CMPX): A Bull Case Theory", "summary": "", "url": "https://news.google.com/rss/articles/CBMihwFBVV95cUxQT3YzMHJyUmtSZktQR1NORnY0QlBxelZCcDFud3N0a0xSM0k0cmhoQXBOd0VvOGdaZ25NdUtFX2tfUFRfMW1oQjVmcmIxUWJYNlhQWVN3ZXRGaGJYeENqbkl2Wm0xLUlXTHMtUXBwNExfYUJjcHdEaUZ3d3JNelVGYjNVR1lMVVU?oc=5", "source_name": "Market source", "published_at": "2026-01-19T08:00:00+00:00", "published_display": "19 Jan 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Assessing Compass Therapeutics (CMPX) Valuation After Strong 1 Year Share Price Performance", "summary": "", "url": "https://news.google.com/rss/articles/CBMilgFBVV95cUxPQ1RNWXlIVjI1eDd2S1VXd2ZoSzFlU1hYcHd5T3BYNE1aeXpZSzVMeF9XTWFaalZKcl96eGtwUDcwNGJUNURCOTZnUXo0R1lZd1l4bU44LUtDWWJGZm1IRVRNcl9wTVFGMXNQZHQ5UlQyLU9rTEVIQjd6b09zcEVZcE1uMEtRek9ZU2NvSTNzTWxpak5zdnc?oc=5", "source_name": "Market source", "published_at": "2026-01-16T08:00:00+00:00", "published_display": "16 Jan 2026 08:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Here's Why Compass Therapeutics, Inc. (CMPX) is a Great Momentum Stock to Buy", "summary": "", "url": "https://news.google.com/rss/articles/CBMihwFBVV95cUxONjVnTzZ0NDg4WUlJTUpmXzVyQXlmeXN3VlN3d203OGQtLWxzaUluak1mN20wWVg4bm14TG13b2JCcHhsVnZub05Wa3p1bWo2Z1haRlNWQTdSUW90NXhwUGxoNGVkTlQyUmZ1eGVPV3laN3R2cU9IbXBSTEpBd09WM2ZuSEJtR1E?oc=5", "source_name": "Market source", "published_at": "2025-12-08T08:00:00+00:00", "published_display": "08 Dec 2025 08:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "CMPX Stock Price and Chart \u2014 NASDAQ:CMPX", "summary": "", "url": "https://news.google.com/rss/articles/CBMiXEFVX3lxTE9hazIxalBESmRsbjZZcnRUNGxLTE84MzdaOUdYdzdobWF3RGJWVklCWElpOE9Bd0k4cXJJaHhQMHZTYTk4T3FfVmJHdWwxdmtSTXNPSU5hMnpRSzVq?oc=5", "source_name": "TradingView", "published_at": "2025-02-09T08:00:00+00:00", "published_display": "09 Feb 2025 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Compass Therapeutics (CMPX) Stock Price, News & Analysis", "summary": "", "url": "https://news.google.com/rss/articles/CBMiWkFVX3lxTE1DNzBBZUVfOThCcGpDOEU4REhSb1h0YmtwTDFvNTNvTUNIYm5hM0t3WVBTYU9Pa1RWYTZCamtIU0pPSU1qeTRxMVFUNHR0OVVwbEZiQTlOY3lDdw?oc=5", "source_name": "MarketBeat", "published_at": "2022-05-17T14:56:03+00:00", "published_display": "17 May 2022 14:56", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "by_tier": {"direct": [{"title": "Compass Therapeutics: A 50% Price Cut Hiding A Regulatory Mispricing Opportunity", "summary": "", "url": "https://news.google.com/rss/articles/CBMixgFBVV95cUxOUjRVUmJWU2hZbFBHelhoWmJ6b3FpMnlWY0FBT3VZWkNaTEEwYXUwVWEyUzliZ2JZaTItb21kbzRDX3BnS3haNUhCSmV3QWhVN1R0NnZ6NThwMFplb1pQbWJMR2NnaGxoRmpaV1RYX1J4MnB3RUNFcVBYb3NLWVdrMk51b0VvM0NJc2FOZkQ4dlFZMGxXODlnRE1WM0V6b3RlSVN1Z0kxRWdSbHRBdUwwdVBIQklEa2I5eDZ4OTJENFkwQXI5RlE?oc=5", "source_name": "Seeking Alpha", "published_at": "2026-07-15T18:31:30+00:00", "published_display": "15 Jul 2026 18:31", "sentiment": "negative", "sentiment_pct": 34, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Compass Therapeutics Inc. (CMPX) Institutional Confidence", "summary": "", "url": "https://news.google.com/rss/articles/CBMicEFVX3lxTE5YSy1GQmg3QS0tbGFwMmpQNVVKTmozU0taOTJmeGxzS01mbHl4NGlXUWhyVDdKOEw4TXdQbHZHLUgtQ3daS0FTd0dGM3h2cFBTNmY4QlVUQzdWYnRqUm9xQlUxeUxGV29HWloyTmxXQkI?oc=5", "source_name": "TradingKey", "published_at": "2026-07-13T07:00:00+00:00", "published_display": "13 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Compass Therapeutics (CMPX) Goldman Sachs 47th Annual Global Healthcare Conference 2026 summary", "summary": "Compass Therapeutics presented at the Goldman Sachs 47th Annual Global Healthcare Conference, highlighting progress on four clinical-stage oncology drugs. The lead asset, tovecimig, is advancing toward potential FDA BLA filing and showed significant efficacy in a phase II/III BTC", "url": "https://quartr.com/events/compass-therapeutics-inc-cmpx-goldman-sachs-47th-annual-global-healthcare-conference-2026_Fe3v2EAo", "source_name": "Quartr", "published_at": "2026-07-08T13:40:55", "published_display": "08 Jul 2026 13:40", "sentiment": "positive", "sentiment_pct": 75, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "CMPX Stock Has Retail Buzzing Ahead Of High-Stakes Cancer Drug Trial Update", "summary": "Compass Therapeutics (CMPX), a biotech company, is generating significant retail investor interest ahead of its Phase 2/3 trial data release for its cancer drug Tovecimig, used to treat advanced biliary tract cancer. The drug, in combination with Paclitaxel, has shown promising e", "url": "https://stocktwits.com/news-articles/markets/equity/cmpx-stock-retail-buzzing-ahead-of-cancer-drug-trial-update/cZBNZa7Re2t", "source_name": "Stocktwits", "published_at": "2026-07-07T20:11:35", "published_display": "07 Jul 2026 20:11", "sentiment": "negative", "sentiment_pct": 42, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "If You Invested $1,000 in Compass Therapeutics Inc (CMPX)", "summary": "This article analyzes the historical performance of investing $1,000 in Compass Therapeutics Inc (CMPX) over different periods, detailing the current worth of such an investment and its annual returns. It also provides a comprehensive overview of Compass Therapeutics, a clinical-", "url": "https://www.stocktitan.net/tools/stock-return-calculator/CMPX", "source_name": "Stock Titan", "published_at": "2026-07-05T00:40:29", "published_display": "05 Jul 2026 00:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Here\u2019s Why Citizens Maintains a Buy on Compass Therapeutics (CMPX)", "summary": "Citizens has reiterated a Market Outperform rating on Compass Therapeutics (CMPX) with a $10 price target after the company presented promising clinical data at the ASCO conference for its bispecific antibody, CTX-8371. This drug showed early signs of activity in treating difficu", "url": "https://www.insidermonkey.com/blog/heres-why-citizens-maintains-a-buy-on-compass-therapeutics-cmpx-1794179/", "source_name": "Insider Monkey", "published_at": "2026-07-03T13:39:52", "published_display": "03 Jul 2026 13:39", "sentiment": "positive", "sentiment_pct": 72, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 93, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Bronstein, Gewirtz & Grossman, LLC Is Investigating Compass Thera", "summary": "Bronstein, Gewirtz & Grossman, LLC is investigating potential claims against Compass Therapeutics, Inc. (CMPX) following a significant drop in its stock price. The investigation stems from an April 27, 2026 announcement regarding a phase 2/3 study for its drug tovecimig, which, d", "url": "https://natlawreview.com/press-releases/bronstein-gewirtz-grossman-llc-investigating-compass-therapeutics-inc-cmpx", "source_name": "The National Law Review", "published_at": "2026-07-02T06:09:32", "published_display": "02 Jul 2026 06:09", "sentiment": "negative", "sentiment_pct": 18, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Compass updates corporate presentation, reports positive Phase 2/3 COMPANION-002 BTC data and plans BLA engagement", "summary": "Compass Therapeutics (`CMPX`) has updated its corporate presentation, revealing positive Phase 2/3 COMPANION-002 data for tovecimig in second-line biliary tract cancer (BTC). The data shows improved objective response rate (ORR) and progression-free survival (PFS) for a combinati", "url": "https://www.tradingview.com/news/tradingview:f4058c1d815a9:0-compass-updates-corporate-presentation-reports-positive-phase-2-3-companion-002-btc-data-and-plans-bla-engagement/", "source_name": "TradingView", "published_at": "2026-07-01T20:39:45", "published_display": "01 Jul 2026 20:39", "sentiment": "positive", "sentiment_pct": 82, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Compass Therapeutics (NASDAQ: CMPX) targets BLA after biliary tract cancer trial success", "summary": "Compass Therapeutics' tovecimig, in combination with paclitaxel, showed significant improvement in overall response rate (18.0% vs. 5.3%) and progression-free survival (4.7 months vs. 2.6 months) in a Phase 2/3 trial for second-line biliary tract cancer. The company plans an FDA ", "url": "https://www.stocktitan.net/sec-filings/CMPX/8-k-compass-therapeutics-inc-reports-material-event-cda7ae44b8fc.html", "source_name": "Stock Titan", "published_at": "2026-07-01T20:39:45", "published_display": "01 Jul 2026 20:39", "sentiment": "positive", "sentiment_pct": 71, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Bronstein, Gewirtz & Grossman, LLC Encourages Compass Therapeutic", "summary": "Bronstein, Gewirtz & Grossman, LLC is investigating potential claims against Compass Therapeutics, Inc. (CMPX) following a significant drop in its stock price. This decline occurred after the company announced phase 2/3 study results for its drug tovecimig, which met a key second", "url": "https://natlawreview.com/press-releases/bronstein-gewirtz-grossman-llc-encourages-compass-therapeutics-inc-cmpx-0", "source_name": "The National Law Review", "published_at": "2026-07-01T19:41:12", "published_display": "01 Jul 2026 19:41", "sentiment": "negative", "sentiment_pct": 8, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to earnings forward of Compass Therapeutics, Inc. \u2013 NASDAQ:CMPX", "summary": "This article focuses on the \"Price to earnings forward\" financial metric for Compass Therapeutics, Inc. (NASDAQ: CMPX). While the article title presents this topic, there is no actual data or discussion provided within the content. The body of the article appears to be primarily ", "url": "https://www.tradingview.com/symbols/NASDAQ-CMPX/financials-statistics-and-ratios/price-earnings-fwd/", "source_name": "TradingView", "published_at": "2026-07-01T01:12:44", "published_display": "01 Jul 2026 01:12", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to sales forward of Compass Therapeutics, Inc. \u2013 NASDAQ:CMPX", "summary": "This page displays the \"Price to sales forward\" metric for Compass Therapeutics, Inc. (NASDAQ: CMPX) as provided by TradingView. The content primarily focuses on financial data for the company within the Pharmaceuticals: Major sector and indicates market closure with no current t", "url": "https://www.tradingview.com/symbols/NASDAQ-CMPX/financials-statistics-and-ratios/price-sales-fwd/", "source_name": "TradingView", "published_at": "2026-06-29T22:10:06", "published_display": "29 Jun 2026 22:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to revenue forward of Compass Therapeutics, Inc. \u2013 NASDAQ:CMPX", "summary": "This article focuses on the \"Enterprise value to revenue forward\" metric for Compass Therapeutics, Inc. (NASDAQ: CMPX). The content is primarily a header with navigation and footer details, indicating a financial data point for the company on the TradingView platform.", "url": "https://www.tradingview.com/symbols/NASDAQ-CMPX/financials-statistics-and-ratios/enterprise-value-sales-fwd/", "source_name": "TradingView", "published_at": "2026-06-29T16:41:25", "published_display": "29 Jun 2026 16:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Compass Therapeutics, Inc.(NasdaqCM:CMPX) dropped from Russell 3000E Growth Benchmark", "summary": "Compass Therapeutics, Inc. (NasdaqCM:CMPX), a clinical-stage biopharmaceutical company focused on oncology therapeutics, has been dropped from the Russell 3000E Growth Benchmark. The company's stock shows a 5-day change of +0.48% and a year-to-date change of -61.27%. Compass Ther", "url": "https://www.marketscreener.com/news/compass-therapeutics-inc-nasdaqcm-cmpx-dropped-from-russell-3000e-growth-benchmark-ce7f5fdeda81f424", "source_name": "www.marketscreener.com", "published_at": "2026-06-29T05:40:07", "published_display": "29 Jun 2026 05:40", "sentiment": "negative", "sentiment_pct": 28, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Compass Therapeutics, Inc.(NasdaqCM:CMPX) dropped from Russell Small Cap Comp Growth Benchmark", "summary": "Compass Therapeutics, Inc. (NasdaqCM:CMPX) has been removed from several Russell benchmarks, including the Russell Small Cap Comp Growth Benchmark, Russell 3000 Growth Benchmark, and Russell Microcap Growth Benchmark Index. This news follows a recent downgrade by Raymond James an", "url": "https://www.marketscreener.com/news/compass-therapeutics-inc-nasdaqcm-cmpx-dropped-from-russell-small-cap-comp-growth-benchmark-ce7f5fdcdb88f721", "source_name": "marketscreener.com", "published_at": "2026-06-28T22:10:06", "published_display": "28 Jun 2026 22:10", "sentiment": "negative", "sentiment_pct": 39, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Compass Therapeutics, Inc. Actuals & Estimates (NASDAQ:CMPX)", "summary": "This article provides an overview of Compass Therapeutics, Inc. (NASDAQ:CMPX) stock data, including its current price, historical performance, and analyst forecasts. It also details the company's financial actuals and estimates, discusses upcoming earnings reports, and provides a", "url": "https://www.tradingview.com/symbols/NASDAQ-CMPX/forecast-actuals-and-estimates/", "source_name": "TradingView", "published_at": "2026-06-25T20:10:07", "published_display": "25 Jun 2026 20:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "CMPX Forecast \u2014 Price Target \u2014 Prediction for 2027", "summary": "This article provides a forecast and price target for Compass Therapeutics, Inc. (CMPX) stock for 2027 based on analyst opinions. It includes current stock performance, historical highs and lows, volatility metrics, and key financial information like recent earnings, revenue, and", "url": "https://www.tradingview.com/symbols/NASDAQ-CMPX/forecast-price-target/", "source_name": "TradingView", "published_at": "2026-06-25T18:42:34", "published_display": "25 Jun 2026 18:42", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Compass Therapeutics Inc. (CMPX) Valuation: PE, PB & Fair Value Analysis", "summary": "This article provides a valuation analysis for Compass Therapeutics Inc. (CMPX), highlighting its current valuation score, market capitalization, and P/E ratio. As of June 26, 2026, the company's valuation score is 8.69, ranking 104 out of 387 in the Biotechnology & Medical Resea", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-cmpx/company-valuation", "source_name": "TradingKey", "published_at": "2026-06-24T08:10:58", "published_display": "24 Jun 2026 08:10", "sentiment": "negative", "sentiment_pct": 38, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Compass Therapeutics (CMPX) Stock Forecast & Analyst Ratings", "summary": "This article provides a stock forecast and analyst ratings for Compass Therapeutics (CMPX). It serves as a resource for investors looking for insights into the company's financial prospects and market sentiment.", "url": "https://www.moomoo.com/stock/CMPX-US/forecast?chain_id=Name1K9-3FXPhg.1ku86o0&global_content=%7B%22promote_id%22%3A%2213764%22,%22sub_promote_id%22%3A%2280%22,%22f%22%3A%22www.moomoo.com%2Fsg%2Flearn%2Fdetail-why-dividend-stocks-can-be-beneficial-to-investors-90963-230159001%22%7D", "source_name": "Moomoo", "published_at": "2026-06-23T13:09:58", "published_display": "23 Jun 2026 13:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Compass Therapeutics Inc. (CMPX) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution", "summary": "This article provides a revenue breakdown for Compass Therapeutics Inc. (CMPX), noting that essential financial data such as business segments, regional revenue, and profit contribution have not yet been disclosed by the company. It only shows a placeholder for \"United States\" wi", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-cmpx/revenue", "source_name": "TradingKey", "published_at": "2026-06-17T17:39:33", "published_display": "17 Jun 2026 17:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "How Compass Therapeutics (CMPX) Is Moving Tovecimig Toward a Potential Biliary Tract Cancer Filing", "summary": "Compass Therapeutics (CMPX) is advancing its experimental cancer treatment, tovecimig, for biliary tract cancer, having received FDA Orphan Drug Designation and planning an approval application later in 2026. The company reported strong tumor response in late-stage studies and ha", "url": "https://www.insidermonkey.com/blog/how-compass-therapeutics-cmpx-is-moving-tovecimig-toward-a-potential-biliary-tract-cancer-filing-1783031/", "source_name": "Insider Monkey", "published_at": "2026-06-17T11:16:00", "published_display": "17 Jun 2026 11:16", "sentiment": "positive", "sentiment_pct": 71, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Compass Therapeutics Inc. (CMPX) Earnings Forecast: Future EPS & Revenue Growth Estimates", "summary": "This article provides an earnings forecast for Compass Therapeutics Inc. (CMPX), highlighting its current earnings forecast score of 8.67 and ranking within the Biotechnology & Medical Research industry. It details analyst ratings, revealing a strong \"Buy\" consensus with an avera", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-cmpx/earnings", "source_name": "TradingKey", "published_at": "2026-06-17T08:11:00", "published_display": "17 Jun 2026 08:11", "sentiment": "positive", "sentiment_pct": 71, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Compass Therapeutics Inc. (CMPX) Financial Health: Profitability & Balance Sheet Analysis", "summary": "This article provides an analysis of Compass Therapeutics Inc. (CMPX) financial health, highlighting its current financial score of 6.36, which ranks it 257 out of 388 in the Biotechnology & Medical Research industry. While the company's financial status is considered robust, its", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-cmpx/financial-health", "source_name": "TradingKey", "published_at": "2026-06-17T08:11:00", "published_display": "17 Jun 2026 08:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Compass Therapeutics Inc. (CMPX) Technical Analysis: Support, Resistance, Indicators & Moving Averages", "summary": "This article provides a technical analysis of Compass Therapeutics Inc. (CMPX), detailing its current price momentum score, support and resistance levels, and indicator readings (MACD, RSI, KDJ, etc.) and moving averages. According to the analysis, CMPX currently has a price mome", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-cmpx/technical", "source_name": "TradingKey", "published_at": "2026-06-17T08:11:00", "published_display": "17 Jun 2026 08:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "5 Small Cap Stocks with Potential to Rise 1000 Percent", "summary": "This article highlights Compass Therapeutics, Inc. (NASDAQ: CMPX) as a small-cap stock with significant growth potential, possibly rising 1000 percent. The company is developing tovecimig, an experimental cancer treatment that recently received FDA Orphan Drug Designation and sho", "url": "https://www.insidermonkey.com/blog/5-small-cap-stocks-with-potential-to-rise-1000-percent-1782074/3/", "source_name": "Insider Monkey", "published_at": "2026-06-16T13:10:07", "published_display": "16 Jun 2026 13:10", "sentiment": "positive", "sentiment_pct": 70, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Compass Therapeutics Shareholders Back Directors, Pay, Auditor Oversight", "summary": "Compass Therapeutics, Inc. shareholders recently re-elected two Class III directors, Thomas J. Schuetz and Richard S. Lindahl, and ratified CohnReznick, LLP as their independent auditor. Investors also approved the compensation for executive officers and supported an annual advis", "url": "https://www.theglobeandmail.com/investing/markets/stocks/CMPX-Q/pressreleases/2448480/compass-therapeutics-shareholders-back-directors-pay-auditor-oversight/", "source_name": "The Globe and Mail", "published_at": "2026-06-14T05:40:56", "published_display": "14 Jun 2026 05:40", "sentiment": "negative", "sentiment_pct": 39, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Transcript : Compass Therapeutics, Inc. Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026, Jun-09-2026 08", "summary": "This article is a transcript of Compass Therapeutics, Inc.'s presentation at the Goldman Sachs 47th Annual Global Healthcare Conference held on June 9, 2026. The presentation started at 8:00 AM. The full article content is reserved for subscribers.", "url": "https://www.marketscreener.com/news/transcript-compass-therapeutics-inc-presents-at-goldman-sachs-47th-annual-global-healthcare-conf-ce7f5cdad981f724", "source_name": "www.marketscreener.com", "published_at": "2026-06-13T17:40:13", "published_display": "13 Jun 2026 17:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Compass Therapeutics (NASDAQ: CMPX) investors back board, auditor and pay in 2026 votes", "summary": "Compass Therapeutics, Inc. stockholders approved all proposals at their annual meeting on June 10, 2026. This included re-electing Class III directors Thomas J. Schuetz and Richard S. Lindahl, ratifying CohnReznick LLP as the independent auditor, and approving executive compensat", "url": "https://www.stocktitan.net/sec-filings/CMPX/8-k-compass-therapeutics-inc-reports-material-event-57f69defd0e2.html", "source_name": "Stock Titan", "published_at": "2026-06-12T15:09:16", "published_display": "12 Jun 2026 15:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "CMPX: Lead oncology asset tovecimig nears FDA filing after strong BTC trial results; multiple catalysts ahead", "summary": "Compass Therapeutics (CMPX) is advancing four oncology assets, with its lead drug, tovecimig, showing strong efficacy in BTC and nearing FDA submission. The company anticipates multiple clinical and regulatory catalysts within the next year and has a cash runway extending into 20", "url": "https://www.tradingview.com/news/urn:summary_document_transcript:quartr.com:3531568:0-cmpx-lead-oncology-asset-tovecimig-nears-fda-filing-after-strong-btc-trial-results-multiple-catalysts-ahead/", "source_name": "TradingView", "published_at": "2026-06-09T13:09:50", "published_display": "09 Jun 2026 13:09", "sentiment": "positive", "sentiment_pct": 71, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Compass Therapeutics Eyes FDA Path After Tovecimig Trial Win", "summary": "Compass Therapeutics is preparing for an FDA meeting in early August regarding its drug tovecimig, a DLL4/VEGF bispecific antibody, after successful trial results in advanced biliary tract cancer. The COMPANION-002 study met its primary endpoint of overall response rate and signi", "url": "https://www.barchart.com/story/news/2378475/compass-therapeutics-eyes-fda-path-after-tovecimig-trial-win", "source_name": "Barchart", "published_at": "2026-06-09T03:10:06", "published_display": "09 Jun 2026 03:10", "sentiment": "positive", "sentiment_pct": 73, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Analysts Offer Insights on Healthcare Companies: Praxis Precision Medicines (PRAX), Compass Therapeutics (CMPX) and Tenax Therapeutics (TENX)", "summary": "This article highlights bullish sentiments from three analysts regarding several healthcare companies. Douglas Tsao from H.C. Wainwright reiterated a Buy rating on Praxis Precision Medicines (PRAX) with a $1245.00 price target. Biren Amin from Piper Sandler maintained a Buy ratin", "url": "https://www.theglobeandmail.com/investing/markets/stocks/PRAX/pressreleases/2259986/analysts-offer-insights-on-healthcare-companies-praxis-precision-medicines-prax-compass-therapeutics-cmpx-and-tenax-therapeutics-tenx/", "source_name": "The Globe and Mail", "published_at": "2026-06-02T13:39:09", "published_display": "02 Jun 2026 13:39", "sentiment": "positive", "sentiment_pct": 77, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Stifel Maintains Compass Therapeutics(CMPX.US) With Buy Rating, Maintains Target Price $6", "summary": "Stifel has reiterated its Buy rating for Compass Therapeutics (CMPX.US) and maintained its price target of $6. The article indicates a continued positive outlook from the financial firm regarding the company's stock.", "url": "https://www.moomoo.com/news/post/70866944/stifel-maintains-compass-therapeutics-cmpxus-with-buy-rating-maintains-target", "source_name": "Moomoo", "published_at": "2026-06-02T10:39:09", "published_display": "02 Jun 2026 10:39", "sentiment": "positive", "sentiment_pct": 75, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Compass Therapeutics to Participate in Upcoming June Investor Events", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/compass-therapeutics-participate-upcoming-june-113000218.html", "source_name": "GlobeNewswire", "published_at": "2026-05-28T11:30:00+00:00", "published_display": "28 May 2026 11:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Compass Therapeutics to Present Promising Phase 1 Clinical Data for CTX-8371 in Patients with Advanced Malignancies Treated in the Post-Checkpoint Inhibitor Setting at the 2026 ASCO Annual Meeting", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "GlobeNewswire", "published_at": "2026-05-21T07:00:00+00:00", "published_display": "21 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Compass Therapeutics, Inc. - CMPX", "summary": "", "url": "https://news.google.com/rss/articles/CBMi-wFBVV95cUxPR2RNMjBRWUhhSGFpZVF1T2pReE05azVLOHhKSzdzd1NuMDFiY0RCb204T1JoUFVpVXhBdXlQR3FGRzdyRkZWVllOb2RjTVhYbzhVa2tiVTFRTU9vMU0xSkk3TU1JeEN4eVBtcE9MeWpka1lTMGowOVFoR01aM0cxZ0QzcmZmVmxVcm1TclE4ZzQxVzA0bjE0RG9HWFFoblc1TVRtMF81THlLZzBiM3FZVHFYY01WS1hvc0pEUW5xa0dJcS1mWHFzWVl4UkJ2UjFFWU9rY1lxcTJXOG5FeHRDMUdRVFF5NDUwLUFMUmNmNmZ3a3ZacjREazhpVQ?oc=5", "source_name": "PR Newswire", "published_at": "2026-05-21T07:00:00+00:00", "published_display": "21 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Compass Therapeutics (CMPX) Reports Q1 2026 Net Loss of $18.3M", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/compass-therapeutics-cmpx-reports-q1-045005286.html", "source_name": "Insider Monkey", "published_at": "2026-05-18T04:50:05+00:00", "published_display": "18 May 2026 04:50", "sentiment": "negative", "sentiment_pct": 42, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Compass Therapeutics to Participate in Upcoming May Investor Events", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/compass-therapeutics-participate-upcoming-may-113000196.html", "source_name": "GlobeNewswire", "published_at": "2026-05-12T11:30:00+00:00", "published_display": "12 May 2026 11:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Canaccord Maintains Buy Rating on Compass Therapeutics (CMPX)", "summary": "", "url": "https://finance.yahoo.com/markets/stocks/articles/canaccord-maintains-buy-rating-compass-121653644.html", "source_name": "Insider Monkey", "published_at": "2026-05-05T12:16:53+00:00", "published_display": "05 May 2026 12:16", "sentiment": "positive", "sentiment_pct": 58, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Compass Therapeutics Reports 2026 First Quarter Financial Results and Provides Corporate Update", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/compass-therapeutics-reports-2026-first-113000530.html", "source_name": "GlobeNewswire", "published_at": "2026-05-05T11:30:00+00:00", "published_display": "05 May 2026 11:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Does Compass Therapeutics' (CMPX) Biliary Cancer Data Hint At A Broader Pipeline Re\u2011Rating Opportunity?", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqwFBVV95cUxQZnFCYUpZOVc1WWNVRlhrTHhmTXhDT3AtR0ZHU1lPQl9yZ3A2VE1odVlJbXJNM3laZV9BUFdieUJna3NMRnhsR1RKb3JYNUUta3VxNmQ5TTIxZ3F2U2hRdlJBNnFBMmVaVlFtZnhGemljbGZOYnZIMDlDU3pEc091c2dZcEJ5Y1JscFB6MmZTcC1RU0Jma2xxZnBBZ181RjB6dWo5TkZGMlNDdDA?oc=5", "source_name": "Market source", "published_at": "2026-04-29T07:00:00+00:00", "published_display": "29 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Compass Therapeutics\u2019s stock crashes after OS miss in BTC trial", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqgFBVV95cUxQZmFCT1dhdHpGTmJFSmNaZUl3M3dlcFB2d0tjbDJUdDhROU83Z1EyQXNwZlBHTGpXbWtWcDlyVmctX3pTdDVZVl8wSlRlSEhvWEF2TTE4djd2T3dzTFpZVU90M1lGdDZrREszcUhzcUNQSjVNam5GZjFJN2N3U1NCWnNxZndLOWt5Tm1BblZjcFBOaVplenhxdC1FSWtTUm10aDlKcmZ3Ql9YUQ?oc=5", "source_name": "Market source", "published_at": "2026-04-28T07:00:00+00:00", "published_display": "28 Apr 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Compass Therapeutics stock tumbles after trial data", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPc0VJcVZqdjYxcjZmRzFQVVBfOFlpTV9qVDZqd1NycGtSYUdHQnZ6SEQ1Q3NUT25ybENKdkxhZmE4RGpCekNpVnFIZ0RESzJXRE9mNnl0eE1EVmVHTVJnSTYxaUtTcnB6U1hpakQyOUhYaUFvZEJzMWFUbk1DR2V5d3lnOWxLcVhDUmhxeEEyMzd1cEp2bTFSY0tlbDlvWDRINjN3eEVrVzlBaS1NTl9FLWUwNA?oc=5", "source_name": "Investing.com", "published_at": "2026-04-27T07:00:00+00:00", "published_display": "27 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "CMPX Stock Slides As Volatility Grips Compass Therapeutics", "summary": "", "url": "https://news.google.com/rss/articles/CBMiggFBVV95cUxNdU1SNjk0WTVuUVoxbnhpUDNsczRJdjVYSV9GMXVkQTBzSVlYd1VDaVdBU2ttR1luaHk1NVZzdER5d3ZrVW9FUUJhbXY0dGFneWJwWUFveEVLamNZLXB5RWhHMFMteE5PZnF6M0ZtaHRiQUllV05IZ0tMOFBRNlU4Skt3?oc=5", "source_name": "timothysykes.com", "published_at": "2026-04-27T07:00:00+00:00", "published_display": "27 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Compass Therapeutics, Inc.'s (NASDAQ:CMPX) Path To Profitability", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqAFBVV95cUxOc0RJN3p1YU1tS3Q4LWc3UXZKQnUwOHcxM3QzQVZTcGNBQlVaSWNZOHd2QU04NzF1Qm1NV1UtMzZpd25LZFZMQUpxVjFBQjhpVTl3X1pqM0lnSGlMV1B0RkJuYXA2UnF1cDA0NWdRbG1TbkFIamo5UWJDcUZ4TGJKSmJYU0NnQVVhbnp0SmJIQjM4SnVSUVpycTdKT1hMTHl1T1N3alRqc0k?oc=5", "source_name": "Market source", "published_at": "2026-04-26T07:00:00+00:00", "published_display": "26 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Compass Therapeutics, Inc. (CMPX) Up 200% Year-on-Year", "summary": "", "url": "https://news.google.com/rss/articles/CBMipAFBVV95cUxOdUJJaF9tRXFGQ3M1djhzaXNvbUdMYnh4Q2VUZjA5VTZ5ZGl0LVNLeVc0RUVobXFWdzRpeTZENFpmaUtqTzMxUmU2VVh5QlQxb2lPZ3VIQ3FCX25oLVNUdkhOV0VKcERaWDVQdTVib21UT1ZhTXBKWTMxU01DdnhwUXlkZ1NpUnlfOUZsRXdzbnEwOXk3SUFUSFZCR2stOGFmMzRadw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "What Compass Therapeutics (CMPX)'s Pipeline Progress And 2025 Losses Reveal About Its Oncology Strategy", "summary": "", "url": "https://news.google.com/rss/articles/CBMikwFBVV95cUxNNERXM3JRYjhsM0FhSHFCQ0l0clAwS2R2Wkp3TW1oRGdYdVdNWURoalF0akNGVDRBc2N6VktUYjFWekVJRjZWcTl6WWRDc2RvZF9pSG5QcTFnajV0QXEyZmhhZlJJMzJxeFV4WDlRTFhmTmdkRGh4VEM3cUxDT0J1VnJkUkU1YjhXeW1IWUFkMGdJLUk?oc=5", "source_name": "Market source", "published_at": "2026-03-09T07:00:00+00:00", "published_display": "09 Mar 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Compass Therapeutics, Inc. (CMPX): A Bull Case Theory", "summary": "", "url": "https://news.google.com/rss/articles/CBMihwFBVV95cUxQT3YzMHJyUmtSZktQR1NORnY0QlBxelZCcDFud3N0a0xSM0k0cmhoQXBOd0VvOGdaZ25NdUtFX2tfUFRfMW1oQjVmcmIxUWJYNlhQWVN3ZXRGaGJYeENqbkl2Wm0xLUlXTHMtUXBwNExfYUJjcHdEaUZ3d3JNelVGYjNVR1lMVVU?oc=5", "source_name": "Market source", "published_at": "2026-01-19T08:00:00+00:00", "published_display": "19 Jan 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Assessing Compass Therapeutics (CMPX) Valuation After Strong 1 Year Share Price Performance", "summary": "", "url": "https://news.google.com/rss/articles/CBMilgFBVV95cUxPQ1RNWXlIVjI1eDd2S1VXd2ZoSzFlU1hYcHd5T3BYNE1aeXpZSzVMeF9XTWFaalZKcl96eGtwUDcwNGJUNURCOTZnUXo0R1lZd1l4bU44LUtDWWJGZm1IRVRNcl9wTVFGMXNQZHQ5UlQyLU9rTEVIQjd6b09zcEVZcE1uMEtRek9ZU2NvSTNzTWxpak5zdnc?oc=5", "source_name": "Market source", "published_at": "2026-01-16T08:00:00+00:00", "published_display": "16 Jan 2026 08:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Here's Why Compass Therapeutics, Inc. (CMPX) is a Great Momentum Stock to Buy", "summary": "", "url": "https://news.google.com/rss/articles/CBMihwFBVV95cUxONjVnTzZ0NDg4WUlJTUpmXzVyQXlmeXN3VlN3d203OGQtLWxzaUluak1mN20wWVg4bm14TG13b2JCcHhsVnZub05Wa3p1bWo2Z1haRlNWQTdSUW90NXhwUGxoNGVkTlQyUmZ1eGVPV3laN3R2cU9IbXBSTEpBd09WM2ZuSEJtR1E?oc=5", "source_name": "Market source", "published_at": "2025-12-08T08:00:00+00:00", "published_display": "08 Dec 2025 08:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "CMPX Stock Price and Chart \u2014 NASDAQ:CMPX", "summary": "", "url": "https://news.google.com/rss/articles/CBMiXEFVX3lxTE9hazIxalBESmRsbjZZcnRUNGxLTE84MzdaOUdYdzdobWF3RGJWVklCWElpOE9Bd0k4cXJJaHhQMHZTYTk4T3FfVmJHdWwxdmtSTXNPSU5hMnpRSzVq?oc=5", "source_name": "TradingView", "published_at": "2025-02-09T08:00:00+00:00", "published_display": "09 Feb 2025 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Compass Therapeutics (CMPX) Stock Price, News & Analysis", "summary": "", "url": "https://news.google.com/rss/articles/CBMiWkFVX3lxTE1DNzBBZUVfOThCcGpDOEU4REhSb1h0YmtwTDFvNTNvTUNIYm5hM0t3WVBTYU9Pa1RWYTZCamtIU0pPSU1qeTRxMVFUNHR0OVVwbEZiQTlOY3lDdw?oc=5", "source_name": "MarketBeat", "published_at": "2022-05-17T14:56:03+00:00", "published_display": "17 May 2022 14:56", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "industry": [{"title": "Q1 Earnings Highs And Lows: Natera (NASDAQ:NTRA) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMilAFBVV95cUxNYmZ3aHMyMjBuNmlEUGN6NWZBZV85cEFWNndJaVNoNEVYNk84MlNKRXJ0RXpRQl9wN1RsekhxM3loY1RRNDJhTnVremtReHhLQWVHS053VzRBUTduSkdqRGt1YkxMMThqZHoydElPX1Zfd3hEMi15VlRwRGRvZ2JqRDFneVVxN0JCYzQ4QlV5TTBEOWx3?oc=5", "source_name": "Market source", "published_at": "2026-07-16T18:49:22+00:00", "published_display": "16 Jul 2026 18:49", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMigAJBVV95cUxPV1hqSFhQM3VfYlNsdldfeVQ1dEdNNzI3S1RTaFJNSThrOXlPSWpMTlR5WWVxNnNsTzhTVGVvTE94R18wa1A0OUdFczBlcTIzeUFBZUt6VVJJMjNqNks3dmRUSzB4cE40anpNekJwUXAwcTFEcVh4QVZCYURXY2w4b2thdk5KZ3ZJMnI1REJObXo5UDdISXVCU1Z2ZVZoVmJpbnEzaDVWVmpGQVNFZzRXYnp0SWRRWWZGSnZnWlJ4aEloNmJBNGRMVFRjb3ZRbmV3QXF5S0pvTV9xNnpaMWV1Z1ZtM3lPdV9RcEdURHlfZFphdjlicEJndW0ybHNBa205?oc=5", "source_name": "The Globe and Mail", "published_at": "2026-07-13T03:32:00+00:00", "published_display": "13 Jul 2026 03:32", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5wFBVV95cUxQcjZqdzdBcURDdWxCZUtoU1dTaHYtVUFRdlo1a3ZGZGY3a1dBX2x2UVE3Y1hoX1duLXhGU2p0UXU2eTctNng5eFJ5c1M0bHBNQ0VmZTFZanhYU21yTVo0UTQtVENveVV1aWdpc3luUlgza3AyUEI2OGx4aEhXc0pBTHpWUThSYXI1S3RTS21lQ21vWjd6MGY4ZDRwVWlEakc3SmFKN09aM0Rlb2pFT3BNNW1GTExnSElFb2NqR3JhX0J3MlptQy1mMk9IOTZtdS1HU25fLU9aOU9XZi1PRDlkZVI2cnhackHSAewBQVVfeXFMTlc2N3pIUkxDd1NtTlVRMEdac1JNSDF3cUNidkZrTElQREZaUTZjZmFHdUVWYW8wcDg1LThGbnlPb0VQUFI4ZXdjSXR6Ym5DREM1X2lyQUtYTzF3XzBBTGRGcEZQQ3FjLWxCQ0locVM2dGZJR1kxYmlBQXdsbFhfbFFISS1wSUkxQmp4U2d2Z3JHbXRPMUpnajBydTRmNnQzZmF5eEdzOVFRNUdDNVV0aDJQNERCaXN3ZGo1UUc1ZGkwOFYzcDgxS1ltZllDeTFxNFIxT3FyOUxLMFNrLUhtOFNFV0xMYkM5TlpWMzk?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}], "sector": []}, "total_fetched": 93, "total_relevant": 61, "sentiment_summary": {"positive": 15, "negative": 12, "neutral": 34, "score": 52, "total": 61, "label": "Balanced news tone", "tone": "neutral"}, "classifier": {"primary_event": "general", "primary_label": "Market update", "confidence": 79, "events": [{"event": "general", "label": "Market update", "weight": 17.6, "count": 32}, {"event": "earnings", "label": "Earnings", "weight": 9.21, "count": 19}, {"event": "analyst", "label": "Analyst action", "weight": 3.3, "count": 6}, {"event": "regulatory", "label": "Regulatory and legal", "weight": 2.0, "count": 3}, {"event": "guidance", "label": "Guidance", "weight": 0.55, "count": 1}], "positive_events": 15, "negative_events": 12}, "market_context": {"has_market_context": true, "latest_close": 2.33, "latest_week": "2026-07-10", "one_week_move": 2.6, "four_week_move": 14.8, "twelve_week_move": -61.2, "trend_signal": "0", "trend_label": "Trend inactive", "trend_tone": "negative", "market_dynamics": -0.904984, "market_dynamics_buy_signal": false, "relative_strength": -52.303011, "fair_value_gap": -11.1, "fair_value_label": "Near fair-value range", "fair_value_tone": "neutral", "expectation_direction": "undecided", "expectation_probability": 49.1645, "reaction_label": "Price confirming higher", "reaction_tone": "positive", "market_sentence": "+2.6% over one week, +14.8% over four weeks, trend inactive, and near fair-value range."}, "interpretation": {"label": "Balanced read", "tone": "neutral", "classification": "balanced", "summary": "News tone and price action are not far from neutral.", "confidence": 60, "badges": [], "opportunities": [], "risks": [], "event_label": "Market update", "sentiment_word": "balanced"}, "charts": {"sources": [{"label": "Market source", "count": 13}, {"label": "TradingView", "count": 9}, {"label": "TradingKey", "count": 6}, {"label": "Insider Monkey", "count": 5}, {"label": "GlobeNewswire", "count": 4}, {"label": "The Globe and Mail", "count": 3}, {"label": "Stock Titan", "count": 3}, {"label": "The National Law Review", "count": 2}], "tiers": [{"label": "Direct company coverage", "count": 52}, {"label": "Industry context", "count": 9}, {"label": "Sector context", "count": 0}], "events": [{"label": "Market update", "count": 32}, {"label": "Earnings", "count": 19}, {"label": "Analyst action", "count": 6}, {"label": "Regulatory and legal", "count": 3}, {"label": "Guidance", "count": 1}]}, "insights": [{"label": "Weighted tone", "value": "52/100", "tone": "neutral", "text": "Balanced news tone"}, {"label": "Market reaction", "value": "Balanced read", "tone": "neutral", "text": "News tone and price action are not far from neutral."}, {"label": "Primary event", "value": "Market update", "tone": "neutral", "text": "79/100 classification confidence."}, {"label": "Company focus", "value": "52", "tone": "positive", "text": "directly relevant articles"}, {"label": "Source quality", "value": "1", "tone": "positive", "text": "high-authority source matches"}, {"label": "Trend context", "value": "Trend inactive", "tone": "negative", "text": "+2.6% over one week, +14.8% over four weeks, trend inactive, and near fair-value range."}, {"label": "Latest direct headline", "value": "Negative", "tone": "negative", "text": "Compass Therapeutics: A 50% Price Cut Hiding A Regulatory Mispricing Opportunity"}], "updated_at": "2026-07-17T09:52:05.406079+00:00", "disclaimer": "Educational market research only. Not financial, investment, trading, tax, or legal advice."}